Soaring Eagle Acquisition Corp.
Status: Deal Closed
U=S+W/5
W=S@11.5
| IPO Proceeds, $M | $1,725.00M |
|---|---|
| IPO Date | Feb 24, 2021 |
| CEO | Harry E. Sloan |
| Left Lead | Goldman Sachs |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24+6 |
| IPO Sector |
General
Not specified |
| IPO Geography | Global |
| Target Company | Ginkgo Bioworks |
| Deal Announced | May 11, 2021 |
| Deal Size, $M | $15,164.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | Sep 14, 2021 |
| Amendment Vote | TBD |
| Closing Date | Sep 17, 2021 |
Formerly SRNG
DNA
DNA/W
| Price | $6.36 $0.16 |
|---|---|
| Last closing price | $6.36 |
| H/L, today | $6.26 / $6.53 |
| H/L, 52-week | $1.12 / $2.94 |
| Volume, today | 172,482 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Soaring Eagle Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 31 filings and events
- 1 underwriters
- 12 deal advisors
- 3 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Harry E. Sloan | 70 | Chief Executive Officer and Chairman |
| Eli Baker | 45 | President, Chief Financial Officer and Secretary |
| Scott M. Delman | 61 | Director |
| Joshua Kazam | 43 | Director |
| Dennis A. Miller | 65 | Director |
| Laurence E. Paul | 56 | Director |
| Isaac Lee | 50 | Director |
| Timothy Leiweke | 63 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Goldman Sachs | BR | 150,000,000 | units |
| 150,000,000 | units | ||
| Up-Front UW fee | 1.50 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.